Science at Sanofi
Events
Stay up to date and register for the latest events and view webinar recordings
ERS 2025 Congress Highlights: Innovations in Respiratory Care and Biologics
Explore key clinical insights and trial data from ERS 2025, including breakthroughs in biologics for asthma and COPD, pediatric asthma management, and AI-enabled respiratory innovation. Curated for healthcare professionals.
![[Post-Webinar] Vaccination in Pregnancy: An Essential Component of Antenatal Care](/.imaging/webp/sanofi-templates/w384-4-3/dam/campus-sanofi-th/science/event/past-event/vip2025/vip_thumbnail.png/jcr:content/vip_thumbnail.png)
EADV 2025 Congress Highlights: Advancing Dermatology Through Science & Innovation
Explore the latest scientific insights and clinical updates from the European Academy of Dermatology and Venereology (EADV) 2025 Congress held in Paris. This year’s sessions spotlighted transformative developments in the management of atopic dermatitis (AD), chronic spontaneous urticaria (CSU), and bullous pemphigoid, with a strong focus on real-world evidence, emerging biologics, and the role of artificial intelligence in dermatology.
Cutting-Edge Science
Discover medical insights and trends from trusted sources and key opinion leaders.
To Be a Detective: Finding Gaucher Patients
Hint 2: How to Differentiate Gaucher Disease Type 1 VS Type 3 And the Likelihood of Symptoms Occurring
ASEAN Delphi Consensus on CRSwNP: Infographic Summary
Explore the ASEAN Delphi Consensus on CRSwNP, highlighting key clinical features, diagnostic considerations, and treatment recommendations in a clear infographic format.
To Be a Detective: Finding Gaucher Patients
Hint 1: All-In-One Tool for Easier Gaucher Patient Identification
Dupilumab Real-World Effectiveness in CRSwNP: AROMA Registry Results
Explore global real-world data from the AROMA registry on dupilumab effectiveness in CRSwNP patients, both surgery-naïve and post-surgery.
Real-Life Indirect Case Matched Comparison of Dupilumab and Tezepelumab on Airway Oscillometry
Updated Evidence from the EVEREST Phase 4 Trial
First, prospective, head-to-head data comparing Dupilumab and Omalizumab in CRSwNP and asthma patients.
Please log in or register to continue reading.
Request-form
